Mucosa analysis

Abstract

The present invention is related to a method for determining mucosa alterations in a subject, in particular to a method for determining mucosa alterations in a sample using a reagent comprising a lanthanide(III) ion, and an array of indicator molecules configured to interact with the sample. The reagent comprising the lanthanide(III) ion does not have any sample or indicator molecule specific recognition elements. The invention relates also to an array for determining mucosa alterations, the array comprising one or more indicator molecules configured to interact specifically with the sample and a reagent comprising a lanthanide(III) ion. The reagent comprising a lanthanide(III) does not have any sample or indicator molecule specific recognition elements.

Claims

1. A method for determining mucosa alterations in sample employing an array of at least two different interacting substances, at least one of which including at least one indicator molecules configured to interact with the sample, the method comprising steps of: a) introducing a solution including the sample to the array, wherein the solution or the array has a reagent including a lanthanide(III) ion, to form at least two admixtures, b) exciting the at least two admixtures at a first excitation wavelength and detecting a signal deriving from the lanthanide(III) ion at a first emission wavelength by using luminescent measurement to obtain a fingerprint of the sample; c) determining a presence or absence of mucosa alterations by comparing the fingerprint of the sample with i) at least one fingerprint of an array obtained from a sample with mucosa alterations, and/or ii) at least one fingerprint of an array obtained from a sample of with no mucosa alterations, in proviso that the reagent including the lanthanide(III) ion does not include any sample or indicator molecule specific recognition elements.

2. The method according to claim 1, wherein the reagent including a lanthanide(III) ion is a luminescent lanthanide(IIII) chelate.

3. The method according to claim 1, wherein the indicator molecule is selected from a pH indicator dye, an ionochromic dye and a tissue stain.

4. The method according to claim 1, wherein the indicator molecule is selected from a group consisting of bromothymol blue, phenyl red, methyl red, litmus, phenolphthalein, neutral red, cresol red, bromocresol blue, EGTA, BAPTA, fura-2, indo-1, murexide, eriochrome black T, alizarin red S, antipyrylazo Ill, xylidyl blue, bromopyrogallol red, calconcarboxylic red, calmagite, 2-mercaptobenzothiazole, arsenazo III. 1-(2-pyridylazo)-2-naphthol, 4-(2-pyridylazo)resorcinol, pyrocatechol violet, 2,6-Bis{[bis(2-pyridylmethyl)amino]methyl}-4-methylphenol, zincon monosodium salt, malachite green, new fuchsin, rhodamine 800, methylene blue, toluidine blue O, brilliant cresyl blue, Wright's stain, eosin B, anilin blue, acid orange, crystal violet, acridine orange, Safranin O, and Tartazin.

5. The method according to claim 1, wherein the mucosa is oral mucosa.

6. The method according to claim 5, wherein the sample is oral rinse.

7. The method according to claim 1, wherein the alterations are related to cancer.

8. An array for determining mucosa alterations in a sample, the array comprising at least two different interacting substances, wherein: (i) at least one of the at least two different interacting substances include at least one indicator molecule configured to interact with mucosa alterations, and wherein (ii) the at least two different interacting substances include a reagent having a lanthanide(III) ion, wherein the reagent having the lanthanide(III) ion does not include any sample or indicator molecule specific recognition elements.

9. The array according to claim 8, wherein the reagent including a lanthanide(III) ion is a luminescent lanthanide(IIII) chelate.

10. The array according to claim 8, wherein the indicator molecule is selected from a pH indicator dye, an ionochromic dye and a tissue stain.

11. The method of claim 2, wherein the indicator molecule is selected from a pH indicator dye, an ionochromic dye and a tissue stain.

12. The method of claim 7, wherein the cancer is head and neck squamous cell carcinoma (HNSCC).

Description

BRIED DESCRIPTION OF DRAWINGS

[0017] FIG. 1 shows exemplary results of the method of the present invention for determining mucosa alterations.

DESCRIPTION

[0018] The present invention concerns a method for determining the presence or absence of mucosa alterations. According to one embodiment the method includes determining mucosa alterations in a sample obtained from a subject employing an array of at least two different interacting substances, at least one of which comprises one or more indicator molecules configured to interact with the sample.

[0019] According one embodiment, the method comprises following steps:

[0020] a) introducing a sample provided from a subject with a reagent comprising a lanthanide(III) ion to form a first admixture;

[0021] b) introducing the first admixture to the at least two interacting substances of the array to form second admixtures;

[0022] c) exciting the second admixtures at a first excitation wavelength, and detecting a signal deriving from the lanthanide(III) ion at a first emission wavelength by using luminescent measurement, to obtain a fingerprint of the sample;

[0023] d) determining the presence or absence of the mucosa alterations in the sample by comparing the fingerprint with

[0024] i) at least one fingerprint of an array obtained from samples with mucosa alterations, and/or

[0025] ii) at least one fingerprint of an array obtained from a samples of with no mucosa alterations,

[0026] in proviso that the reagent comprising a lanthanide(III) ion does not comprise sample or indicator molecule specific recognition elements.

[0027] According to another embodiment the method of the present invention includes determining mucosa alterations in a sample obtained from a subject employing an array of at least two different interacting substances and a reagent comprising a lanthanide(III) ion, at least one of the interacting substances comprising one or more indicator molecules configured to interact with the sample, the method comprises the following steps:

[0028] a) introducing a sample provided from a subject to the array to obtain at least two admixtures;

[0029] b) exciting the admixtures at a first excitation wavelength, and detecting a signal deriving from the lanthanide(III) ion at a first emission wavelength by using luminescent measurement to obtain a fingerprint of the sample;

[0030] c) determining the presence or absence of the mucosa alterations by comparing the fingerprint with

[0031] i) at least one fingerprint of an array obtained from samples with mucosa alterations, and/or

[0032] ii) at least one fingerprint of an array obtained from a samples of with no mucosa alterations,

[0033] in proviso that the reagent comprising a lanthanide(III) ion does not comprise sample or indicator molecule specific recognition elements.

[0034] A mucous membrane or mucosa is a lining of mostly endodermal origin. It consists of an epithelium (a layer, or layers of epithelial cells) and an underlying lamina propria of loose connective tissue. Mucosae line various cavities of the body that are either externally exposed to the environment or are internal organs, and the mucous membranes ensure that the underlying lamina propria of connective tissue remains moist. They are at several places contiguous with skin: at the nostrils, the lips of the mouth, the eyelids, the ears, the trachea, the stomach, the genital area, and the anus. Exemplary mucosae are ronchial mucosa, endometrium, esophageal mucosa, gastric mucosa, intestinal mucosa, nasal mucosa, olfactory mucosa, oral mucosa, penile mucosa, and vaginal mucosa. According to a preferable embodiment the mucosa is oral mucosa.

[0035] As defined herein, an alteration is any abnormality in the tissue of an organism. If an alteration is caused by a tumor it is classified as malignant or benign.

[0036] According to a preferable embodiment the method is used for determining alterations in oral mucosa. According to this embodiment the sample is selected from the group consisting of oral rinse, saliva, and sputum. A preferable bodily fluid is oral rinse. If required, the sample can be purified or diluted prior to analysis. Exemplary purification methods are chromatography and filtration.

[0037] According to one embodiment, the sample is admixed with a reagent comprising a lanthanide(III) ion. The lanthanide is preferably selected from europium, terbium, samarium and dysprosium, preferably from europium and terbium. The most preferable lanthanide is europium.

[0038] The reagent comprising lanthanide ion is preferably a luminescent lanthanide(III) chelate. Exemplary luminescent lanthanide(III) chelates comprising a pyridine subunit as a part of the chromophore moiety have been disclosed in Bioconjugate Chem. 2009, 20, 404. An exemplary luminescent lanthanide(III) chelate is a terpyridine-Eu(III) (1)

##STR00001##

[0039] The reagent comprising a lanthanide(III) ion is allowed to chelate and/or coordinate with the sample including one or more sample substances, such as mucous proteins. The reagent comprising a lanthanide(III) ion does not have any sample specific recognition elements and thus it is able to coordinate and/or chelate with the sample non-specifically.

[0040] According to one embodiment a solution including the sample and a reagent comprising a lanthanide(III) ion is admixed with an array comprising one or more indicator molecules. The indicator molecule is configured to interact with the sample, sample coordinated and/or chelated with reagent comprising a lanthanide(III) ion and/or with the reagent comprising a lanthanide(III) ion. According to the invention, interaction of the indicator with the reagent comprising a lanthanide(III) ion is non-specific, while interaction of the indicator with the sample substance is specific. The term non-specific interaction means that binding or other interaction is not predetermined.

[0041] According to another embodiment, the array comprises the one or more indicator molecules and the reagent comprising a lanthanide(III) ion, and the sample is admixed with the array to give rise to two or more admixtures, preferably two or more solutions comprising the indicator moleculesnts, the sample, and the reagent comprising a lanthanide(III) ion.

[0042] The indicator molecules are preferably selected from pH indicator dyes, ionochromic dyes and tissue stains. Exemplary pH indicator dyes are bromothymol blue, phenyl red, methyl red, litmus, phenolphthalein, neutral red, cresol red, bromocresol blue. Exemplary ionochromic dyes are Ca dyes EGTA, BAPTA, fura-2, indo-1, murexide, eriochrome black T, alizarin red S, antipyrylazo III, Mg dyes xylidyl blue, bromopyrogallol red, calconcarboxylic red, calmagite, Cd dyes 2-mercaptobenzothiazole and arsenazo III and dyes for other metals 1-(2pyridylazo)-2-naphthol, 4-(2-pyridylazo)resorcinol, pyrocatechol violet, 2,6-Bis{[bis(2-pyridylmethyl)amino]methyl}-4-methylphenol, zincon monosodium salt. Exemplary tissue stains are methylene blue, toluidine blue O, brilliant cresyl blue, Wright's stain, eosin B, anilin blue, acid orange, crystal violet, acridine orange, Safranin O, and Tartazin. Exemplary other suitable dyes are malachite green, new fuchsin, and rhodamine 800.

[0043] The lanthanide(III) ion is detected preferably using time-gated luminescence. Any TRF reader can be employed. Excitation and emission wavelengths can be selected so that the S/N is the best. Also the delay time can be optimized. According to an exemplary embodiment the lanthanide(III) ion is europium and the excitation and emission wavelength is 395 nm and 615 nm, respectively. An exemplary delay time for europium is 400 s. When other lanthanides, i.e. terbium, samarium or dysprosium are used, the excitation and emission wavelengths and the delay time are chosen based on the requirements of the lanthanide ion.

[0044] The presence or absence of mucosa alterations is determined by comparison with a reference fingerprints obtained from samples of population of healthy individuals and samples of population of individuals including mucosa alterations. Typical results are shown in FIG. 1. Accordingly, the present method is able to separate samples including mucosa alterations from mucosa samples with no alterations.

EXPERIMENTAL

[0045] A Typical Procedure

[0046] Mouth of a subject was rinsed with 20-25 ml of physiological salt solution. Sample was then collected and stored in a freezer if not analyzed immediately. Eu-terpyridine chelate (1) was admixed with the sample to give a chelate concentration of 0.76 nM. A 70 L of the admixture was dispersed to a microtiter plate containing the dyes. After a 10 min incubation at ambient temperature, the signal derived from the europium(III) ion was measured with Labrox plate reader (excitation wavelength 340 nm; emission wavelength. 615 nm). Final concentrations and exemplary dye compositions are collected in Table 1.

TABLE-US-00001 TABLE 1 # Indicator c (M) c (M) Dye sensitivity 1 o-cresolphtalein 1006 salts/metal ions complexone 2 EGTA + EosinB 50 52 proteins 3 EGTA + pyrocathecol 50 101 salts violet 4 3-HPA + bromocresol 50 71 pH/albumin purple

[0047] The measurement results are shown in FIG. 1. The data was divided to a separate teaching and testing sets. The presence of alterations in the measured fingerprints was predicted for the test set by using a k-nearest neighbor's algorithm trained with the training set. The accuracy of the prediction of alterations was 90% for the test set. The algorithm is able to differentiate the samples of healthy subjects and samples of subjects having mucosa alterations.

[0048] The specific examples provided in the description given above should not be construed as limiting the scope and/or the applicability of the appended claims.